{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:27:39Z","timestamp":1781594859163,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA100707"],"award-info":[{"award-number":["P50 CA100707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA155258"],"award-info":[{"award-number":["P01CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RO1 CA 207237"],"award-info":[{"award-number":["RO1 CA 207237"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA100707"],"award-info":[{"award-number":["P50 CA100707"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA155258"],"award-info":[{"award-number":["P01CA155258"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RO1 CA 207237"],"award-info":[{"award-number":["RO1 CA 207237"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1038\/s41375-020-0745-9","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T13:03:13Z","timestamp":1581685393000},"page":"2150-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma"],"prefix":"10.1038","volume":"34","author":[{"given":"Lijie","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kinneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"745_CR1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2011.94","volume":"25","author":"DK Walters","year":"2011","unstructured":"Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, et al. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia. 2011;25:1344\u201353.","journal-title":"Leukemia."},{"key":"745_CR2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","volume":"20","author":"F Cottini","year":"2014","unstructured":"Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599\u2013606.","journal-title":"Nat Med."},{"key":"745_CR3","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","volume":"5","author":"F Cottini","year":"2015","unstructured":"Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, et al. Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Discov. 2015;5:972\u201387.","journal-title":"Cancer Discov."},{"key":"745_CR4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449\u201356.","journal-title":"Cancer Res."},{"key":"745_CR5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32:2636\u201347.","journal-title":"Leukemia."},{"key":"745_CR6","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","volume":"22","author":"R Szalat","year":"2016","unstructured":"Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res. 2016;22:5434\u201342.","journal-title":"Clin Cancer Res"},{"key":"745_CR7","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.","journal-title":"Nat Commun"},{"key":"745_CR8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384\u201390.","journal-title":"Leukemia."},{"key":"745_CR9","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.","journal-title":"Nat Rev Dis Prim"},{"key":"745_CR10","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H. Introduction to the review series on advances in multiple myeloma. Blood. 2019;133:621.","DOI":"10.1182\/blood-2018-11-877795"},{"key":"745_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JOP.18.00311","volume":"14","author":"KC Anderson","year":"2018","unstructured":"Anderson KC. Promise of immune therapies in multiple myeloma. J Oncol Pract. 2018;14:411\u20133.","journal-title":"J Oncol Pract"},{"key":"745_CR12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329\u201337.","journal-title":"Blood."},{"key":"745_CR13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol."},{"key":"745_CR14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl J Med. 2015;373:1207\u201319.","journal-title":"N. Engl J Med"},{"key":"745_CR15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"745_CR16","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","volume":"2","author":"PG Richardson","year":"2015","unstructured":"Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2:e516\u201327.","journal-title":"Lancet Haematol"},{"key":"745_CR17","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","volume":"16","author":"S Lonial","year":"2016","unstructured":"Lonial S, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2016;16:1291\u2013301.","journal-title":"Expert Opin Biol Ther"},{"key":"745_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/fon-2017-0371","volume":"14","author":"M Offidani","year":"2018","unstructured":"Offidani M, Corvatta L. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. Future Oncol. 2018;14:319\u201329.","journal-title":"Future Oncol."},{"key":"745_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13\u201329.","journal-title":"Blood."},{"key":"745_CR20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","volume":"23","author":"K Tzogani","year":"2018","unstructured":"Tzogani K, Penninga E, Schougaard Christiansen ML, Hovgaard D, Sarac SB, Camarero Jimenez J, et al. EMA review of daratumumab for the treatment of adult patients with multiple myeloma. Oncologist. 2018;23:594\u2013602.","journal-title":"Oncologist."},{"key":"745_CR21","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","volume":"25","author":"S Coats","year":"2019","unstructured":"Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS, et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019;25:5441\u20138.","journal-title":"Clin Cancer Res"},{"key":"745_CR22","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood."},{"key":"745_CR23","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187\u201399.","journal-title":"Immunotherapy."},{"key":"745_CR24","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential sses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.","journal-title":"Front Immunol."},{"key":"745_CR25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"YT Tai","year":"2019","unstructured":"Tai YT, Anderson KC. BCMA-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19:1143\u201356.","journal-title":"Expert Opin Biol Ther"},{"key":"745_CR26","doi-asserted-by":"crossref","unstructured":"Cho SF, Lin L, Xing L, Yu T, Wen K, Anderson KC, et al. Monoclonal antibody: a new treatment strategy against multiple myeloma. Antibodies (Basel). 2017;6. pii: E18.","DOI":"10.3390\/antib6040018"},{"key":"745_CR27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174:911\u201322.","journal-title":"Br J Haematol"},{"key":"745_CR28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641\u201353.","journal-title":"Lancet Oncol."},{"key":"745_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.","journal-title":"Blood Cancer J."},{"key":"745_CR30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726\u201337.","journal-title":"N. Engl J Med"},{"key":"745_CR31","doi-asserted-by":"crossref","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129:2210\u201321.","DOI":"10.1172\/JCI126397"},{"key":"745_CR32","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267\u201380.","journal-title":"J Clin Oncol"},{"key":"745_CR33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:1743\u201351.","journal-title":"Leukemia."},{"key":"745_CR34","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","volume":"37","author":"MS Topp","year":"2019","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. J Clin Oncol. 2019;37:8007.","journal-title":"J Clin Oncol"},{"key":"745_CR35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","volume":"33","author":"K Kinneer","year":"2019","unstructured":"Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, et al. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia. 2019;33:766\u201371.","journal-title":"Leukemia."},{"key":"745_CR36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42\u201351.","journal-title":"Lancet Oncol."},{"key":"745_CR37","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131:1094\u2013105.","journal-title":"Blood."},{"key":"745_CR38","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","volume":"14","author":"N Dimasi","year":"2017","unstructured":"Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, et al. Efficient preparation of site-specific antibody-drug conjugates using cysteine insertion. Mol Pharm. 2017;14:1501\u201316.","journal-title":"Mol Pharm."},{"key":"745_CR39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30:399\u2013408.","journal-title":"Leukemia."},{"key":"745_CR40","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"YT Tai","year":"2012","unstructured":"Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120:1877\u201387.","journal-title":"Blood."},{"key":"745_CR41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365.","journal-title":"Leukemia."},{"key":"745_CR42","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225\u201336.","journal-title":"Blood."},{"key":"745_CR43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1204258","volume":"333","author":"DT Long","year":"2011","unstructured":"Long DT, Raschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science. 2011;333:84\u20137.","journal-title":"Science."},{"key":"745_CR44","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1158\/1078-0432.CCR-16-0083","volume":"23","author":"AB Lin","year":"2017","unstructured":"Lin AB, McNeely SC, Beckmann RP. Achieving precision death with cell-cycle inhibitors that target DNA replication and repair. Clin Cancer Res. 2017;23:3232\u201340.","journal-title":"Clin Cancer Res"},{"key":"745_CR45","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"KG Pike","year":"2018","unstructured":"Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N. et al. The identification of potent, selective, and orally available inhibitors of Ataxia Telangiectasia Mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J Med Chem. 2018;61:3823\u201341.","journal-title":"J Med Chem."},{"key":"745_CR46","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018;61:9889\u2013907.","journal-title":"J Med Chem"},{"key":"745_CR47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2018.1511700","volume":"27","author":"S Fu","year":"2018","unstructured":"Fu S, Wang Y, Keyomarsi K, Meric-Bernstam F, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs. 2018;27:741\u201351.","journal-title":"Expert Opin Investig Drugs"},{"key":"745_CR48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res."},{"key":"745_CR49","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","volume":"118","author":"P Neri","year":"2011","unstructured":"Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, et al. Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118:6368\u201379.","journal-title":"Blood."},{"key":"745_CR50","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.4049\/jimmunol.165.11.6347","volume":"165","author":"YT Tai","year":"2000","unstructured":"Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000;165:6347\u201355.","journal-title":"J Immunol."},{"key":"745_CR51","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0301-472X(01)00786-X","volume":"30","author":"YT Tai","year":"2002","unstructured":"Tai YT, Podar K, Kraeft SK, Wang F, Young G, Lin B, et al. Translocation of Ku86\/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol. 2002;30:212\u201320.","journal-title":"Exp Hematol."},{"key":"745_CR52","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3324\/haematol.11435","volume":"92","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, et al. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica. 2007;92:1505\u201312.","journal-title":"Haematologica."},{"key":"745_CR53","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1517\/14712598.2013.814637","volume":"13 (Suppl 1)","author":"P Neri","year":"2013","unstructured":"Neri P, Bahlis NJ. Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opin Biol Ther. 2013;13 (Suppl 1):S69\u201382.","journal-title":"Expert Opin Biol Ther."},{"key":"745_CR54","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","volume":"127","author":"M Cea","year":"2016","unstructured":"Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016;127:1138\u201350.","journal-title":"Blood."},{"key":"745_CR55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/leu.2017.182","volume":"32","author":"R Szalat","year":"2018","unstructured":"Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, et al. Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018;32:111\u20139.","journal-title":"Leukemia."},{"key":"745_CR56","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/0008-5472.CAN-09-4428","volume":"70","author":"S Chen","year":"2010","unstructured":"Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010;70:4318\u201326.","journal-title":"Cancer Res."},{"key":"745_CR57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.V100.1.224","volume":"100","author":"VJ Spanswick","year":"2002","unstructured":"Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood. 2002;100:224\u20139.","journal-title":"Blood."},{"key":"745_CR58","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2016-01-691618","volume":"128","author":"M Gkotzamanidou","year":"2016","unstructured":"Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood. 2016;128:1214\u201325.","journal-title":"Blood."},{"key":"745_CR59","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","volume":"15","author":"MJ Flynn","year":"2016","unstructured":"Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther. 2016;15:2709\u201321.","journal-title":"Mol Cancer Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0745-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0745-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:03:29Z","timestamp":1705082609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0745-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0745-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"3 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KK is an employee of AstraZeneca and has stock and\/or stock interests in AstraZeneca. NM serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. KCA serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}